Skip to main content
Erschienen in:

15.01.2024 | Research

Laparoscopic Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Metastasis: Improved Short-term Outcomes Revealed Through Propensity Score Matching Analysis

verfasst von: Nicolò Bortoli, Marco Tonello, Elisa Pizzolato, Carola Cenzi, Pierluigi Pilati, Antonio Sommariva

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is the standard of care for selected cases of primary or secondary peritoneal surface malignancies. The study aims to verify the postoperative advantages of laparoscopic CRS-HIPEC.

Methods

A retrospective analysis of patients who underwent CRS-HIPEC at our institution was performed. Records were extracted from a prospectively maintained database. Patients were divided into two groups, laparoscopic CRS-HIPEC and open CRS-HIPEC, and matched for age, ASA, comorbidities, Prior Surgical Score (PSS), and Peritoneal Cancer Index (PCI) using propensity score analysis. Demographics, clinical, and operative data were compared between the two groups using chi-square or Fisher’s exact test and T-test or Mann–Whitney U test.

Results

Between 2016 and 2022, 13 patients underwent laparoscopic CRS-HIPEC. These were matched to 32 open CRS-HIPEC patients (1:2.5), obtaining comparable demographics and clinical and preoperative variables. The two groups had a similar duration and complexity of surgery; however, the mean estimated blood loss was lower during laparoscopic procedures (p = 0.008). Overall morbidity rates were lower after laparoscopic CRS-HIPEC (p = 0.043); however, grade III-IV complications, reintervention, and 90-day readmission rates were comparable between the two groups. A faster postoperative recovery in all aspects of the postoperative course was observed, including hospital length of stay (6 vs. 9.5 days, p = 0.003).

Conclusions

Laparoscopic CRS-HIPEC is a feasible and safe procedure and shows improved short-term postoperative outcomes in selected patients with limited peritoneal disease compared to the open approach.
Literatur
2.
Zurück zum Zitat Kusamura S, Barretta F, Yonemura Y, et al. The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery. JAMA Surg. 2021;156(3). Kusamura S, Barretta F, Yonemura Y, et al. The role of hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei after cytoreductive surgery. JAMA Surg. 2021;156(3).
3.
Zurück zum Zitat Kusamura S, Baratti D, De Simone M, et al. Diagnostic and therapeutic pathway in diffuse malignant peritoneal mesothelioma. Cancers (Basel). 2023;15(3). Kusamura S, Baratti D, De Simone M, et al. Diagnostic and therapeutic pathway in diffuse malignant peritoneal mesothelioma. Cancers (Basel). 2023;15(3).
4.
Zurück zum Zitat van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–40.CrossRefPubMed van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018;378(3):230–40.CrossRefPubMed
5.
Zurück zum Zitat Quénet F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256–66.CrossRefPubMed Quénet F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256–66.CrossRefPubMed
6.
Zurück zum Zitat Martins M, Santos-Sousa H, Araújo F, Nogueiro J, Sousa-Pinto B. Impact of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer with peritoneal carcinomatosis: a systematic review and meta-analysis. Ann Surg Oncol. 2022;29(12):7528–37.CrossRefPubMed Martins M, Santos-Sousa H, Araújo F, Nogueiro J, Sousa-Pinto B. Impact of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer with peritoneal carcinomatosis: a systematic review and meta-analysis. Ann Surg Oncol. 2022;29(12):7528–37.CrossRefPubMed
7.
Zurück zum Zitat Hübner M, Kusamura S, Villeneuve L, et al. Guidelines for perioperative care in cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC): enhanced recovery after surgery (ERAS®) Society Recommendations - Part I: Preoperative and intraoperative management. Eur J Surg Oncol. 2020;46(12):2292–310.CrossRefPubMed Hübner M, Kusamura S, Villeneuve L, et al. Guidelines for perioperative care in cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC): enhanced recovery after surgery (ERAS®) Society Recommendations - Part I: Preoperative and intraoperative management. Eur J Surg Oncol. 2020;46(12):2292–310.CrossRefPubMed
8.
Zurück zum Zitat Hübner M, Kusamura S, Villeneuve L, et al. Guidelines for perioperative care in cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC): enhanced recovery after surgery (ERAS®) Society Recommendations — Part II: Postoperative management and special considerations. Eur J Surg Oncol. 2020;46(12):2311–23.CrossRefPubMed Hübner M, Kusamura S, Villeneuve L, et al. Guidelines for perioperative care in cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC): enhanced recovery after surgery (ERAS®) Society Recommendations — Part II: Postoperative management and special considerations. Eur J Surg Oncol. 2020;46(12):2311–23.CrossRefPubMed
9.
Zurück zum Zitat Arjona-Sanchez A, Aziz O, Passot G, et al. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry. Eur J Surg Oncol. 2021;47(6):1420–1426. Arjona-Sanchez A, Aziz O, Passot G, et al. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry. Eur J Surg Oncol. 2021;47(6):1420–1426.
10.
Zurück zum Zitat Sommariva A, Valle M, Gelmini R, et al. Laparoscopic cytoreduction combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal surface malignancies (PSM): Italian PSM oncoteam evidence and literature review. Cancers (Basel). 2022;15(1). Sommariva A, Valle M, Gelmini R, et al. Laparoscopic cytoreduction combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal surface malignancies (PSM): Italian PSM oncoteam evidence and literature review. Cancers (Basel). 2022;15(1).
11.
Zurück zum Zitat Paul BK, Ihemelandu C, Sugarbaker PH. Prior surgical score: an analysis of the prognostic significance of an initial nondefinitive surgical intervention in patients with peritoneal carcinomatosis of a colorectal origin undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy. Dis Colon Rectum. 2018;61(3):347–54.CrossRefPubMed Paul BK, Ihemelandu C, Sugarbaker PH. Prior surgical score: an analysis of the prognostic significance of an initial nondefinitive surgical intervention in patients with peritoneal carcinomatosis of a colorectal origin undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy. Dis Colon Rectum. 2018;61(3):347–54.CrossRefPubMed
12.
Zurück zum Zitat Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.CrossRefPubMedCentralPubMed Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.CrossRefPubMedCentralPubMed
13.
Zurück zum Zitat Portilla AG, Shigeki K, Dario B, Marcello D. The intraoperative staging systems in the management of peritoneal surface malignancy. J Surg Oncol. 2008;98(4):228–31.CrossRefPubMed Portilla AG, Shigeki K, Dario B, Marcello D. The intraoperative staging systems in the management of peritoneal surface malignancy. J Surg Oncol. 2008;98(4):228–31.CrossRefPubMed
14.
Zurück zum Zitat Sugarbaker PH. Preoperative assessment of cancer patients with peritoneal metastases for complete cytoreduction. Indian J Surg Oncol. 2016;7(3):295–302.CrossRefPubMedCentralPubMed Sugarbaker PH. Preoperative assessment of cancer patients with peritoneal metastases for complete cytoreduction. Indian J Surg Oncol. 2016;7(3):295–302.CrossRefPubMedCentralPubMed
15.
Zurück zum Zitat Dasari BVM, Baker J, Markar S, Gardiner K. Laparoscopic appendicectomy in obese is associated with improvements in clinical outcome: systematic review. Int J Surg. 2015;13:250–6.CrossRefPubMed Dasari BVM, Baker J, Markar S, Gardiner K. Laparoscopic appendicectomy in obese is associated with improvements in clinical outcome: systematic review. Int J Surg. 2015;13:250–6.CrossRefPubMed
16.
Zurück zum Zitat Antoniou SA, Antoniou GA, Koch OO, Köhler G, Pointner R, Granderath FA. Laparoscopic versus open obesity surgery: a meta-analysis of pulmonary complications. Dig Surg. 2015;32(2):98–107.CrossRefPubMed Antoniou SA, Antoniou GA, Koch OO, Köhler G, Pointner R, Granderath FA. Laparoscopic versus open obesity surgery: a meta-analysis of pulmonary complications. Dig Surg. 2015;32(2):98–107.CrossRefPubMed
17.
Zurück zum Zitat Tekkis PP, Senagore AJ, Delaney CP. Conversion rates in laparoscopic colorectal surgery: a predictive model with, 1253 patients. Surg Endosc. 2005;19(1):47–54.CrossRefPubMed Tekkis PP, Senagore AJ, Delaney CP. Conversion rates in laparoscopic colorectal surgery: a predictive model with, 1253 patients. Surg Endosc. 2005;19(1):47–54.CrossRefPubMed
18.
Zurück zum Zitat Walker JL, Piedmonte MR, Spirtos NM, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol. 2009;27(32):5331–6.CrossRefPubMedCentralPubMed Walker JL, Piedmonte MR, Spirtos NM, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol. 2009;27(32):5331–6.CrossRefPubMedCentralPubMed
19.
Zurück zum Zitat Shaltiel T, Solomon D, Pletcher ER, et al. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is associated with improved perioperative outcomes: a single-center early experience propensity-matched analysis. Surg Endosc. 2022;36(8):6153–61.CrossRefPubMed Shaltiel T, Solomon D, Pletcher ER, et al. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is associated with improved perioperative outcomes: a single-center early experience propensity-matched analysis. Surg Endosc. 2022;36(8):6153–61.CrossRefPubMed
20.
Zurück zum Zitat Chang SC, Fingerhut A, Chen WTL. Short and long-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal and appendiceal cancer peritoneal metastasis: propensity score-matched comparison between laparoscopy vs. open approaches. Surg Oncol. 2022;43. Chang SC, Fingerhut A, Chen WTL. Short and long-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for colorectal and appendiceal cancer peritoneal metastasis: propensity score-matched comparison between laparoscopy vs. open approaches. Surg Oncol. 2022;43.
21.
Zurück zum Zitat Rodríguez-Ortiz L, Arjona-Sánchez A, Ibañez-Rubio M, et al. Laparoscopic cytoreductive surgery and HIPEC: a comparative matched analysis. Surg Endosc. 2021;35(4):1778–85.CrossRefPubMed Rodríguez-Ortiz L, Arjona-Sánchez A, Ibañez-Rubio M, et al. Laparoscopic cytoreductive surgery and HIPEC: a comparative matched analysis. Surg Endosc. 2021;35(4):1778–85.CrossRefPubMed
Metadaten
Titel
Laparoscopic Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Metastasis: Improved Short-term Outcomes Revealed Through Propensity Score Matching Analysis
verfasst von
Nicolò Bortoli
Marco Tonello
Elisa Pizzolato
Carola Cenzi
Pierluigi Pilati
Antonio Sommariva
Publikationsdatum
15.01.2024
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 2/2024
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-024-01014-w

Neu im Fachgebiet Onkologie

Polypen bei nahen Verwandten – erhöhtes Darmkrebsrisiko

Werden bei erstgradigen Verwandten gutartige Darmpolypen identifiziert, ist das Risiko, selbst an einem Kolorektalkarzinom zu erkranken, deutlich erhöht – vor allem das für eine früh beginnende Erkrankung. Hier könnte sich eine frühe Koloskopie besonders lohnen.

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Welche Krebserkrankungen bei Zöliakie häufiger auftreten

Eine große Kohortenstudie hat den Zusammenhang zwischen Zöliakie und gastrointestinalen Krebserkrankungen und inflammatorischen Krankheiten untersucht. Neben gastrointestinalen Tumoren ist auch ein nicht solider Krebs häufiger.

Adjuvanter PD-L1-Hemmer verhindert Rezidive bei Hochrisiko-Urothelkarzinom

Sind Menschen mit muskelinvasivem Urothelkarzinom für die neoadjuvante platinbasierte Therapie nicht geeignet oder sprechen sie darauf nicht gut an, ist Pembrolizumab eine adjuvante Alternative: Die krankheitsfreie Lebenszeit wird dadurch mehr als verdoppelt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.